CCL5 increases lung cancer migration via PI3K, Akt and NF-κB pathways

中國醫藥大學機構典藏 China Medical University Repository, Taiwan > 北港附設醫院 > 期刊論文 > Item 310903500/3227

請使用永久網址來引用或連結此文件: http://ir.cmu.edu.tw/ir/handle/310903500/3227

題名:	CCL5 increases lung cancer migration via PI3K, Akt and NF-κB pathways
作者:	黃俊寅(Chun-Yin Huang);馮逸卿(Yi-Chin Fong);李俊億(Chun-Yi Lee);陳孟意(Meng-Yi Chen);蔡筱琪(Hsiao-Chi Tsai);許弘昌(Horng-Chaung Hsu);湯智昕(Tang Chih-Hsin)*
貢獻者:	北港醫院骨科
關鍵詞:	CCL5;Lung cancer;Migration;Akt;PI3K
日期:	2009-03
上傳時間:	2009-08-20 18:09:18 (UTC+8)
摘要:	CCL5 (previously called RANTES) is in the CC-chemokine family and plays a crucial role in the migration and metastasis of human cancer cells. Besides, integrins are the major adhesive molecules in mammalian cells. Here we found CCL5 increased the migration and cell surface expression of αvβ3 integrin in human lung cancer cells (A549 cells). CCL5 stimulation increased phosphorylation of the p85α subunit of phosphatidylinositol 3-kinase (PI3K) and serine 473 of Akt. Also, we found that PI3K inhibitor (Ly294002) or Akt inhibitor suppressed CCL5-induced migration activities and integrin expression of A549 cells. Transfection of cells with p85 or Akt mutant also reduced CCL5-mediated cancer migration. In addition, treatment of A549 cells with CCL5 induced IκB kinase α/β (IKK α/β) phosphorylation, IκB phosphorylation, p65 Ser536 phosphorylation, and κB-luciferase activity. Furthermore, the CCL5-mediated increases in p65 Ser536 phosphorylation were inhibited by Ly294002 and Akt inhibitor. Taken together, our results suggest that CCL5 acts through PI3K/Akt, which in turn activates IKKα/β and NF-κB, resulting in the activation of αvβ3 integrin and contributing to the migration of human lung cancer cells.
關聯:	BIOCHEMICAL PHARMACOLOGY 77(5):794~803
顯示於類別:	[北港附設醫院] 期刊論文

文件中的檔案:

檔案	大小	格式	瀏覽次數
	58Kb	Unknown	839	檢視/開啟

在CMUR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....